Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Taiwan Liposome Company Ltd (4152) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7996)・商品コード:DATA904C7996
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:33
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Taiwan Liposome Company Ltd (TLC) is a clinical-stage pharmaceutical company that develops and commercializes novel nanomedicines based on drug delivery technology platform. The company’s pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma. TLC holds expertise in lipid-based formulation and scale-up of parental drugs from nanoparticles for optimizing the pharmacokinetics of drugs. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of oncology, ophthalmology and oncology. The company has operations in Taiwan, the US, Japan and the Netherlands. TLC is headquartered in Taipei, Taiwan.

Taiwan Liposome Company Ltd (4152) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10
Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11
Taiwan Liposome and Ablynx Enter into Research Agreement 12
Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13
Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14
Licensing Agreements 15
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16
Equity Offering 17
Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17
Taiwan Liposome to Raise Funds through Private Placement of Shares 19
Taiwan Liposome Completes Public Offering Of Shares For US$10 Million 20
Taiwan Liposome Completes Public Offering Of US$100 Million 21
Acquisition 22
Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22
Taiwan Liposome Company Ltd – Key Competitors 23
Taiwan Liposome Company Ltd – Key Employees 24
Taiwan Liposome Company Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Product News 26
10/16/2017: TLC Showcases Pain Drug Candidate TLC590 at Janney’s Osteoarthritis & Pain Therapeutic Forum 26
10/11/2017: TLC to Present Update on Anesthetic Drug Candidate TLC590 at Janney’s Osteoarthritis & Pain Therapeutic Forum 27
01/09/2017: Results of Phase 1/2 Clinical Trial of TLC599 in the Treatment of Osteoarthritis of the Knee 28
Product Approvals 29
Apr 03, 2018: TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug 29
Clinical Trials 30
Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399 30
Jul 11, 2017: TLC Announces Issuance of Patent for Dexamethasone Sodium Phosphate 31
Jan 03, 2017: TLC to Proceed with TLC599 Phase 2 Trial in Taiwan 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10
Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11
Taiwan Liposome and Ablynx Enter into Research Agreement 12
Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13
Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16
Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17
Taiwan Liposome to Raise Funds through Private Placement of Shares 19
Taiwan Liposome Completes Public Offering Of Shares For US$10 Million 20
Taiwan Liposome Completes Public Offering Of US$100 Million 21
Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22
Taiwan Liposome Company Ltd, Key Competitors 23
Taiwan Liposome Company Ltd, Key Employees 24
Taiwan Liposome Company Ltd, Other Locations 25
Taiwan Liposome Company Ltd, Subsidiaries 25

List of Figures
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7996)販売に関する免責事項を必ずご確認ください。
★調査レポート[Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆